Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Patient-Reported Outcomes and Medication Adherence in Patients with Heart Failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Protective association of angiotensin blockade with influenza: A result of immortal time bias?

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Am I going to die now? Experiences of hospitalisation and subsequent life after being diagnosed with aortic dissection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exercise-based cardiac rehabilitation for adults after heart valve surgery

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

AIMS: Patient-reported outcome measures (PROMs) may predict poor clinical outcome in patients with heart failure (HF). It remains unclear whether PROMs are associated with subsequent adherence to HF medication. We aimed to determine whether health-related quality of life, anxiety, and depression were associated with long-term medication adherence in these patients.

METHODS AND RESULTS: A national cohort study of Danish patients with HF with 3-year follow-up (n = 1464). PROMs included the EuroQol five-dimensional, five-level questionnaire (EQ-5D-5L), the HeartQoL and the Hospital Anxiety and Depression Scale (HADS). Patient-reported outcomes (PRO) data were linked to demographic and clinical data at baseline, and data on all redeemed prescriptions for angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor neprilysin inhibitors (ACEI/ARB/ARNI), β-blockers, and mineralocorticoid receptor antagonists during follow-up. Medication non-adherence was defined as <80% of proportion of days covered. In adjusted regression analyses, lower health-related quality of life (EQ-5D and HeartQoL) and symptoms of depression (HADS-D) at discharge were associated with non-adherence. After 3 years of follow-up, lower health-related quality of life (EQ-5D) was associated with non-adherence for ACEI/ARB/ARNI [adjusted OR 2.78, 95% confidence interval (CI): 1.19-6.49], β-blockers (adjusted OR 2.35, 95% CI: 1.04-5.29), whereas HADS-D was associated with non-adherence for ACEI/ARB/ARNI (adjusted OR 1.07, 95% CI: 1.03-1.11) and β-blockers (adjusted OR 1.06, 95% CI: 1.02-1.10).

CONCLUSION: Lower health-related quality of life and symptoms of depression were associated with non-adherence across HF medications at 1 and 3 years of follow-up. Person-centred care using PROMs may carry a potential for identifying patients at increased risk of future medication non-adherence.

OriginalsprogEngelsk
TidsskriftEuropean heart journal. Cardiovascular pharmacotherapy
Vol/bind7
Udgave nummer4
Sider (fra-til)287-295
Antal sider9
ISSN2055-6837
DOI
StatusUdgivet - 1 jul. 2021

Bibliografisk note

© Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2020. For permissions, please email: journals.permissions@oup.com.

ID: 62329852